Article Details

A Study of Pharmacovigilance System Performing Intensive and Monitoring in HIV/AIDS | Original Article

Deepak Chawla*, Chagi Venkatesh, in Journal of Advances in Science and Technology | Science & Technology


The objective of the present study is to analyze national and international pharmacovigilance data for potential signals in the pharmacovigilance data analysis. Vigiflow software was used to assess causality, seriousness, severity of spontaneous adverse drug reaction reportage formulas as described in the National Pharmacovigilance Program and to enter the WHO database. WHO experts evaluated these data and certification was made by WHO for the entry of data in Vigiflow. In relation to important information, which led to difficulties carrying out the causality assessment, the ADR forms reported under the National Pharmacovigilance Program were not complete. This is not only because healthcare professionals know about the importance of ADR reporting, but also because there are no columns in the ADR form itself that provide some important facts necessary to evaluate causality. Pharmacovigilance in India hasn't been very advanced. This may be because the health workers are ignorant and the drug safety surveillance is not properly trained. The facts generated in other countries, advisory notes issued and regulatory measures taken by regulators elsewhere depend heavily on India. However, if circumstances differ, information obtained in one country may not be relevant to any other part of the world. This requires us to produce indigenous data that would be more significant and have an educational value and could contribute to national decision-making on regulatory matters. It is therefore important to develop a strong system of pharmacovigilance. The pharmacovigilance system involves minimizing existing risks through health care provider training, secured health care provision, assessment of new risk by different pharmacovigilance methods, such as active or passive supervision, analysis of pharmacovigilance-generated safety data, the identification of preventive risks, and risk development.